References
- Ciftciler R, Haznedaroglu IC. 2021. Tailored tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) based on current evidence. Eur Rev Med Pharmacol Sci. 25:7787–7798.
- Cushman M, Nagarathnam D, Gopal D, Geahlen RL. 1991. Synthesis and evaluation of new protein-tyrosine kinase inhibitors. Part 1. pyridine-containing stilbenes and amides. Bioorg Med Chem Lett. 1(4):211–214. doi: 10.1016/S0960-894X(00)80254-1.
- Di Gion P, Kanefendt F, Lindauer A, Scheffler M, Doroshyenko O, Fuhr U, Wolf J, Jaehde U. 2011. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. Clin Pharmacokinet. 50(9):551–603. doi: 10.2165/11593320-000000000-00000.
- Duan YC, Jin LF, Ren HM, Zhang SJ, Liu YJ, Xu YT, He ZH, Song Y, Yuan H, Chen SH, et al. 2021. Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer. Eur J Med Chem. 220:113453. doi: 10.1016/j.ejmech.2021.113453.
- Jabbour E, Kantarjian H. 2020. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol. 95(6):691–709. doi: 10.1002/ajh.25792.
- Koh Y-C, Ho C-T, Pan M-H. 2021. Recent Advances in Health Benefits of Stilbenoids. J Agric Food Chem. 69(35):10036–10057. doi: 10.1021/acs.jafc.1c03699.
- Kostoudi S, Pampalakis G. 2022. Improvements, Variations and Biomedical Applications of the Michaelis-Arbuzov Reaction. Int J Mol Sci. 23(6):3395. doi: 10.3390/ijms23063395.
- Lin X, Li Y, Zhong W, Hong T, Li L, Song S, He D. 2021. Synthesis, bioactivity, and QSAR study of 3,4-dichlorophenyl isoxazole-substituted stilbene derivatives against the phytopathogenic fungus Botrytis cinerea. J Agric Food Chem. 69(33):9520–9528. doi: 10.1021/acs.jafc.1c01816.
- Ling Y, Hao ZY, Liang D, Zhang CL, Liu YF, Wang Y. 2021. The expanding role of pyridine and dihydropyridine scaffolds in drug design. Drug Des Devel Ther. 15:4289–4338. doi: 10.2147/DDDT.S329547.
- Ma Z, Han X, Ren J, Liu K, Zhang W, Li G. 2023. Design, synthesis, and biological activity of guaiazulene derivatives. Chem Biodivers. 20(2):e202201174.
- Martí-Centelles R, Murga J, Falomir E, Carda M, Alberto Marco J. 2015. Inhibitory effect of cytotoxic nitrogen-containing heterocyclic stilbene analogues on VEGF protein secretion and VEGF, hTERT and c-Myc gene expression. Med Chem Commun. 6(10):1809–1815. doi: 10.1039/C5MD00197H.
- Newman DJ, Cragg GM. 2020. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J Nat Prod. 83(3):770–803. doi: 10.1021/acs.jnatprod.9b01285.
- Pan Y-L, Zeng S-X, Hao R-R, Liang M-H, Shen Z-R, Huang W-H. 2022. The progress of small-molecules and degraders against BCR-ABL for the treatment of CML. Eur J Med Chem. 2022/08/05/238:114442. doi: 10.1016/j.ejmech.2022.114442.
- Sahu R, Mishra R, Kumar R, Majee C, Mazumder A, Kumar A, Salahuddin. 2022. Pyridine moiety: an insight into recent advances in the treatment of cancer.Mini Rev Med Chem, 22:248–272. doi: 10.2174/1389557521666210614162031.
- Sawyers CL. 1999. Chronic myeloid leukemia. N Engl J Med. 340(17):1330–1340. doi: 10.1056/NEJM199904293401706.
- Sviripa VM, Zhang W, Balia AG, Tsodikov OV, Nickell JR, Gizard F, Yu T, Lee EY, Dwoskin LP, Liu C, et al. 2014. 2',6'-Dihalostyrylanilines, pyridines, and pyrimidines for the inhibition of the catalytic subunit of methionine S-adenosyltransferase-2. J Med Chem. 57(14):6083–6091.2014/06/21. doi: 10.1021/jm5004864.